SUBSCRIBE
SUBSCRIBE
News   Drug Development

Pfizer Inc.'s Axitinib Shows Promise in Kidney Cancer

October 31, 2007 | 
1 min read

LONDON, Oct 30 (Reuters) - Pfizer Inc’s experimental drug axitinib has shown promise for treating patients with advanced kidney cancer, slowing the disease for six months or more in some cases, according to a study published on Tuesday.

Clinical research Phase II Europe
Pfizer
MORE ON THIS TOPIC
US Dollar coin and EU currencies on weighing scale against Unated States and European Union flags as symbol of trade war, economic conflict. Selective focus on Dollar.
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
 · 
3 min read
 · 
Annalee Armstrong
Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VII
Obesity
Eli Lilly Keeps Obesity Pipeline Fresh With $1.3B Superluminal Partnership
August 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Pipeline
Schrödinger Cans Early-Stage Blood Cancer Drug After Two Patient Deaths
August 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Conceptual business illustration of upcoming business problem metaphor with falling domino and businessman silhouette. Minimalistic vector eps 10 illustration
Inflammatory bowel disease
CytomX Reports Treatment-Related Patient Death in Phase I Colorectal Cancer Study
August 14, 2025
 · 
2 min read
 · 
Tristan Manalac